|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0009647,
umls-concept:C0010583,
umls-concept:C0030705,
umls-concept:C0035015,
umls-concept:C0040808,
umls-concept:C0059985,
umls-concept:C0332161,
umls-concept:C0392756,
umls-concept:C0422792,
umls-concept:C0522510,
umls-concept:C1274040,
umls-concept:C1504389,
umls-concept:C1515895,
umls-concept:C1527178,
umls-concept:C1548437,
umls-concept:C1705938,
umls-concept:C1882923,
umls-concept:C1883018
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2007-6-20
|
|
pubmed:abstractText |
Thirty-five patients (25 men and 10 women) with a median age of 20 years with severe aplastic anaemia (SAA) underwent HLA identical stem cell transplantation (HSCT) using a combination of fludarabine and cyclophosphamide +/- anti-thymocyte globulin between 2004 and 2006. Cyclosporine and mini methotrexate were used as GVHD prophylaxis. Graft source included peripheral blood stem cells (28) or G-CSF stimulated bone marrow (7). Two patients expired < 7 days post-HSCT while 32 (91.5%) patients engrafted with a median neutrophil and platelet engraftment time of 12 days each. Three patients (8.5%) developed veno-occlusive disease while acute GVHD occurred in 29% of evaluable patients, with chronic GVHD in 32%. At a mean follow-up of 22 months, 29 (82.8%) are alive and well. When compared with 26 patients previously transplanted using Cy200/antilymphocyte globulin, there was faster neutrophil engraftment (12 vs 16 days; P = 0.002) with significantly lower rejection rates (2.9 vs 30.7%; P = 0.003) and a superior event-free (82.8 vs 38.4%; P = 0.001) and overall survival (82.8 vs 46.1%; P = 0.005). A combination of fludarabine with cyclophosphamide +/- anti-thymocyte globulin reduces rejection and improves overall and event-free survival in Indian patients undergoing HSCT for severe aplastic anaemia.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0268-3369
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
13-8
|
|
pubmed:meshHeading |
pubmed-meshheading:17450183-Adult,
pubmed-meshheading:17450183-Anemia, Aplastic,
pubmed-meshheading:17450183-Antilymphocyte Serum,
pubmed-meshheading:17450183-Cyclophosphamide,
pubmed-meshheading:17450183-Enzyme Inhibitors,
pubmed-meshheading:17450183-Female,
pubmed-meshheading:17450183-Graft vs Host Disease,
pubmed-meshheading:17450183-Humans,
pubmed-meshheading:17450183-Immunosuppressive Agents,
pubmed-meshheading:17450183-India,
pubmed-meshheading:17450183-Male,
pubmed-meshheading:17450183-Retrospective Studies,
pubmed-meshheading:17450183-Stem Cell Transplantation,
pubmed-meshheading:17450183-Survival Analysis,
pubmed-meshheading:17450183-Transplantation, Homologous,
pubmed-meshheading:17450183-Transplantation Conditioning,
pubmed-meshheading:17450183-Treatment Outcome,
pubmed-meshheading:17450183-Vidarabine
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Fludarabine and cyclophosphamide based reduced intensity conditioning (RIC) regimens reduce rejection and improve outcome in Indian patients undergoing allogeneic stem cell transplantation for severe aplastic anemia.
|
|
pubmed:affiliation |
Department of Haematology, Christian Medical College, Vellore, Tamil Nadu, India. biju@cmcvellore.ac.in
|
|
pubmed:publicationType |
Journal Article
|
